Navigation Links
SinoFresh(R) Nasal Spray Kills MRSA 'Super-Bug' in Live Noses

SinoFresh(R) Passes First Key Test for Potential to Control 'Super-Bug'


VENICE, Fla., Aug. 19 /PRNewswire-FirstCall/ -- SinoFresh HealthCare, Inc., (OTC Bulletin Board: SFSH) announced preliminary results today from a successful in vivo pilot study indicating that its patented SinoFresh(R) nasal spray was shown to be useful in controlling the MRSA "super-bug" in the nasal passages. This study utilized a recognized scientific model intended to demonstrate SinoFresh(R) nasal spray's ability to kill MRSA hiding in the nasal passages. These favorable efficacy results follow an earlier, successful in vitro study that was conducted at the Public Health Research Institute under the direction of Dr. Barry Kreiswirth, director of the Tuberculosis Center and Hospital Infections Program.

The study showed that "SinoFresh(R) nasal spray used three times daily appeared to effectively eliminate MRSA in the noses of the test animals while leaving enough normal microbes to keep a normal population in the nasal passages," according to Dr. John Todhunter, consultant to SinoFresh, who oversaw the study conducted at Virion Systems in Rockville, MD.

MRSA (which stands for Methicillin Resistant Staphylococcus aureus) is a growing concern in the health care community. It incubates in the nasal passages and then gets on the skin where it can cause severe, virulent infections. The effect of MRSA can lead to disfigurement and sometimes death. MRSA is also highly antibiotic resistant, making MRSA infections difficult to treat. It is believed that approximately 2 - 3 million persons in the U.S. walk around carrying MRSA in their nasal passages at any time and elimination or severe reduction of nasal MRSA colonies is seen as a potentially important weapon in fighting the spread of MSRA. The antibiotic Mupirocin is currently used to reduce nasal MRSA loads.

SinoFresh(R) nasal spray attacks MRSA in the nasal passages by destroying the "super-bug's" cell walls and membranes by physical means rather than by an antibiotic mechanism involving attack on the metabolism of the microbes as occurs with the use of antibiotics. "Since bacteria can in effect change their metabolism to be resistant to antibiotics, but can't very well change the laws of physics the chances for development of resistance to SinoFresh(R) Nasal Spray's mode of killing them is much lower said Dr. Todhunter."

According to William Wilferth, VP for Research and Development at SinoFresh, "These results have exceeded our expectations. The positive results of this in vivo study gives us the solid scientific platform we have needed in order to advance our efforts to fight MRSA to the next level."

Charles Fust, CEO of SinoFresh, noted that the data reported is extremely encouraging and that there is a significant market need for new methods to address MRSA control which is believed to be as many as 80 to 100 million treatments annually in the United States alone.

About SinoFresh HealthCare, Inc.

SinoFresh HealthCare, Inc. (OTC BB: SFSH.OB - News) is a developer and marketer of innovative upper respiratory system therapies. The company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial and fungal organisms that are suspected to cause pathogenesis of the mouth, nose and throat. The company's lead product, SinoFresh(R) Nasal and Sinus Care, is a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants. The company is also researching how antiseptic cleansing may alleviate chronic sinus distress, a condition that may affect 37 million Americans annually. SinoFresh(R) products are available in major retail outlets nationwide. More information is available at


William Wilferth, R. Ph. M.S.

VP Research & Development

SinoFresh HealthCare, Inc.

787 Commerce Drive / Suite 6

Venice, FL 34292

Tel: (941) 488-9090 / e-mail:

SOURCE SinoFresh HealthCare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nasal Anthrax Vaccine Proves Effective in Animal Study
2. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
3. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
4. Nosefrida Nasal Aspirator - A Parents Alternative to Medicines on the Verge of FDA Ban
5. As Cold & Flu Season Nears, New Baby Nasal Aspirator Offers Safe and Effective Alternative to FDA-Discouraged Medicines
6. U.S. Advisers OK Nasal Spray Flu Vaccine for Young Children
7. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
8. Saline Irrigation Eases Chronic Nasal Symptoms
9. Protein Nasal Spray Revives Sleep-Deprived Monkeys
10. Saline Nasal Wash Helps Kids Fight Colds, Flu
11. Nasal polyps from analgesics
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a ... component is distributed nationally, through a vast social media strategy and across a ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
(Date:11/27/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk ... Term Support) into its Q-Suite 5.10 product line. , Making the change to ... of Asterisk that will receive not only security fixes, but feature and bug ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... Ein neuer Kombinationsansatz vereint ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... Clinical Cancer Research vom 6. November ... vom 6. November 2015 berichtet. --> ...
(Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
Breaking Medicine Technology: